Drugs / MK-0249
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00874939 | Apr 2009 | Alzheimer disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00620659 | Feb 2008 → Feb 2009 | hypersomnia, obstructive sleep apnea syndrome | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00506077 | Dec 2007 → Oct 2008 | paranoid schizophrenia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00475735 | Jul 2007 → Apr 2008 | attention deficit-hyperactivity disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00420420 | Nov 2006 → Aug 2008 | Alzheimer disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-0249 | “Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with...” PMID 23920422 ↗ Aug 20138“Mild-to-moderate AD patients were randomized 1:1 to 4 weeks of double-blind daily treatment with oral MK-0249 5-mg or placebo.” PMID 22272611 ↗ May 2012 “We evaluated whether the H3 inverse agonist MK-0249 might improve cognitive deficits in patients with schizophrenia.” PMID 23523692 ↗ Mar 2013 “MK-0249, 10 mg per day was taken orally daily.” NCT00475735 ↗ |
| Action | Inhibit | “We performed a clinical trial to evaluate the effects of the histamine subtype-3 receptor inverse agonist MK- 0249 on cognition in AD patients.” PMID 22272611 ↗ May 2012 |
| Modality | Small molecule | — CHEMBL476323 ↗ |
| Route | Oral | “Mild-to-moderate AD patients were randomized 1:1 to 4 weeks of double-blind daily treatment with oral MK-0249 5-mg or placebo.” PMID 22272611 ↗ May 2012 |
| Target | HRH3 | “Histamine H3 receptor inverse agonist” CHEMBL476323 ↗ |